Will Purdue Bankruptcy Filing Resolve 'Unrelenting Chaos' Of Opioid Litigation?
Executive Summary
Filing stays litigation but state attorneys general will be battling company's settlement proposal in US bankruptcy court. Details emerge on Purdue finances, rebate expenditures and litigation costs.
You may also be interested in...
Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
Did OxyContin Labeling Change Help Fuel Opioid Epidemic? Republicans Want More Data From FDA
Members of House Energy & Commerce Committee reiterate concerns that 2001 label revision may have been used to help promote higher dosage and longer-term prescriptions of OxyContin. J&J boosts opioid litigation settlement offer to $5bn.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: